Literature DB >> 20959535

Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats.

Gene Hsiao1, Justin Chapman, Jachelle M Ofrecio, Jason Wilkes, Jamie L Resnik, Divya Thapar, Shankar Subramaniam, Dorothy D Sears.   

Abstract

Peroxisome proliferator-activated receptor-γ (PPARγ) ligands, including the insulin-sensitizing thiazolidinedione drugs, transcriptionally regulate hundreds of genes. Little is known about the relationship between PPARγ ligand-specific modulation of cellular mechanisms and insulin sensitization. We characterized the insulin sensitivity and multitissue gene expression profiles of lean and insulin-resistant, obese Zucker rats untreated or treated with one of four PPARγ ligands (pioglitazone, rosiglitazone, troglitazone, and AG-035029). We analyzed the transcriptional profiles of adipose tissue, skeletal muscle, and liver from the rats and determined whether ligand treatment insulin-sensitizing potency was related to ligand treatment-induced alteration of functional pathways. Ligand treatments improved insulin sensitivity in obese rats to varying degrees. Adipose tissue profiles revealed ligand treatment-selective modulation of inflammatory and branched-chain amino acid (BCAA) metabolic pathways, which correlated with ligand treatment-specific insulin-sensitizing potency. Skeletal muscle profiles showed that obese rats exhibited elevated expression of adipocyte and slow-twitch fiber markers, which further increased after ligand treatment, but the magnitude of the treatment-induced changes was not correlated with insulin sensitization. Although PPARγ ligand treatments heterogeneously improved dysregulated expression of cholesterol and fatty acid biosynthetic pathways in obese rat liver, these alterations were not correlated with ligand insulin-sensitizing potency. PPARγ ligand treatment-specific insulin-sensitizing potency correlated with modulation of adipose tissue inflammatory and BCAA metabolic pathways, suggesting a functional relationship between these pathways and whole body insulin sensitivity. Other PPARγ ligand treatment-induced functional pathway changes were detected in adipose tissue, skeletal muscle, and liver profiles but were not related to degree of insulin sensitization.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959535      PMCID: PMC3023199          DOI: 10.1152/ajpendo.00219.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  51 in total

Review 1.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

Authors:  J M Olefsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  The origin of intermuscular adipose tissue and its pathophysiological implications.

Authors:  Roberto Vettor; Gabriella Milan; Chiara Franzin; Marta Sanna; Paolo De Coppi; Rosario Rizzuto; Giovanni Federspil
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-09-08       Impact factor: 4.310

3.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

Authors:  H S Camp; O Li; S C Wise; Y H Hong; C L Frankowski; X Shen; R Vanbogelen; T Leff
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

4.  Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.

Authors:  C D Toseland; S Campbell; I Francis; P J Bugelski; N Mehdi
Journal:  Diabetes Obes Metab       Date:  2001-06       Impact factor: 6.577

5.  Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.

Authors:  A L Hevener; D Reichart; A Janez; J Olefsky
Journal:  Diabetes       Date:  2001-10       Impact factor: 9.461

6.  Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes.

Authors:  A M Fernández; J K Kim; S Yakar; J Dupont; C Hernandez-Sanchez; A L Castle; J Filmore; G I Shulman; D Le Roith
Journal:  Genes Dev       Date:  2001-08-01       Impact factor: 11.361

7.  Mechanism of amino acid-induced skeletal muscle insulin resistance in humans.

Authors:  Michael Krebs; Martin Krssak; Elisabeth Bernroider; Christian Anderwald; Attila Brehm; Martin Meyerspeer; Peter Nowotny; Erich Roth; Werner Waldhäusl; Michael Roden
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

8.  Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization.

Authors:  D D Sears; G Hsiao; A Hsiao; J G Yu; C H Courtney; J M Ofrecio; J Chapman; S Subramaniam
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

9.  Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice.

Authors:  Justin Chapman; Philip D Miles; Jachelle M Ofrecio; Jaap G Neels; Joseph G Yu; Jamie L Resnik; Jason Wilkes; Saswata Talukdar; Divya Thapar; Kristen Johnson; Dorothy D Sears
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

10.  PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization.

Authors:  Shigeki Sugii; Peter Olson; Dorothy D Sears; Maziyar Saberi; Annette R Atkins; Grant D Barish; Suk-Hyun Hong; Glenda L Castro; Yun-Qiang Yin; Michael C Nelson; Gene Hsiao; David R Greaves; Michael Downes; Ruth T Yu; Jerrold M Olefsky; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-16       Impact factor: 11.205

View more
  46 in total

1.  Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss.

Authors:  S H Shah; D R Crosslin; C S Haynes; S Nelson; C B Turer; R D Stevens; M J Muehlbauer; B R Wenner; J R Bain; B Laferrère; P Gorroochurn; J Teixeira; P J Brantley; V J Stevens; J F Hollis; L J Appel; L F Lien; B Batch; C B Newgard; L P Svetkey
Journal:  Diabetologia       Date:  2011-11-08       Impact factor: 10.122

Review 2.  Metabolomics and Metabolic Diseases: Where Do We Stand?

Authors:  Christopher B Newgard
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

Review 3.  Branched-chain amino acids in metabolic signalling and insulin resistance.

Authors:  Christopher J Lynch; Sean H Adams
Journal:  Nat Rev Endocrinol       Date:  2014-10-07       Impact factor: 43.330

4.  Gene-expression measurement: variance-modeling considerations for robust data analysis.

Authors:  Shankar Subramaniam; Gene Hsiao
Journal:  Nat Immunol       Date:  2012-02-16       Impact factor: 25.606

Review 5.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

6.  5'AMP-activated protein kinase activity is increased in adipose tissue of northern elephant seal pups during prolonged fasting-induced insulin resistance.

Authors:  Jose A Viscarra; Cory D Champagne; Daniel E Crocker; Rudy M Ortiz
Journal:  J Endocrinol       Date:  2011-03-23       Impact factor: 4.286

Review 7.  Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state.

Authors:  Sean H Adams
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

Review 8.  Insulin resistance and the metabolism of branched-chain amino acids.

Authors:  Jingyi Lu; Guoxiang Xie; Weiping Jia; Wei Jia
Journal:  Front Med       Date:  2013-02-06       Impact factor: 4.592

9.  Branched Chain Amino Acids.

Authors:  Michael Neinast; Danielle Murashige; Zoltan Arany
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

10.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Authors:  Pilar Caro; Amar U Kishan; Erik Norberg; Illana A Stanley; Bjoern Chapuy; Scott B Ficarro; Klaudia Polak; Daniel Tondera; John Gounarides; Hong Yin; Feng Zhou; Michael R Green; Linfeng Chen; Stefano Monti; Jarrod A Marto; Margaret A Shipp; Nika N Danial
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.